{"changes":[],"country":"US","description":"NewLimit is a biotechnology company developing medicines that restore youthful function to old cells by reprogramming the epigenome. It targets patients with age-related diseases of the liver, immune, and vascular systems. Rather than altering DNA, it reverses cellular aging through epigenetic reprogramming guided by single-cell genomics.","domain":"newlimit.com","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":37.65354,"lng":-122.416866,"location":"South San Francisco, United States","name":"NewLimit","rounds":[{"amountQuarantined":false,"amountUsd":130000000,"currency":"USD","date":"2025-05-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-07","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"newlimit-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-07","status":"attributed","url":null},{"fact":"existence","publisher":"newlimit.com","retrievedAt":"2026-06-07","status":"self-reported","url":"https://newlimit.com"},{"fact":"description","publisher":"newlimit.com","retrievedAt":"2026-06-07","status":"self-reported","url":"https://newlimit.com"}],"stage":"series-b+","techStack":["cloudflare","doubleclick floodlight","google font api","google hosted libraries","hsts","http/3","jquery 3.5.1","mysql","php","vercel speed insights","wordpress"],"totalRaisedUsd":347000000,"updatedAt":"2026-06-07"}